Drug Manufacturers - Specialty & Generic · Healthcare
Head of Investor Relations, CFO, Chief Accounting Officer
2023-08-14–present
Head of Investor Relations
Canopy Growth Corp (CGC)Chief Accounting Officer
Canopy Growth Corp (CGC)Equibles does not estimate personal net worth.
Get an email with a short summary when Canopy Growth Corp publishes a filing, an earnings call transcript or a press release.
Get CGC alertsJudy Hong is recorded as Chief Accounting Officer at Canopy Growth Corp (CGC) since August 14, 2023 and Head of Investor Relations and CFO at Canopy Growth Corp (CGC). The newest filing on record that lists Judy Hong as CFO at Canopy Growth Corp (CGC) is dated August 7, 2026. Canopy Growth Corp reported in an 8-K filed July 9, 2025 that Judy Hong was terminated as Chief Financial Officer, effective July 9, 2025. Canopy Growth Corp reported in an 8-K filed August 17, 2023 that Judy Hong was appointed Principal Accounting Officer, effective August 14, 2023. The proxy statement of Canopy Growth Corp reports total compensation of $2,303,063 for Judy Hong in fiscal 2024, including a base salary of $410,960. Disclosed compensation is on record for 3 fiscal years. Judy Hong has spoken on 19 earnings calls across 1 company, most recently for Canopy Growth Corp on May 30, 2025. Canopy Growth Corp is classified in the Drug Manufacturers - Specialty & Generic industry within the Healthcare sector. Other leadership on record at Canopy Growth Corp includes Luc Mongeau (CEO and Board Member), Judy A (Chairman), Thomas Stewart (CFO and Chief Accounting Officer) and 7 others.
“On July 9, 2025, Canopy Growth Corporation (the "Company") terminated the employment of its Chief Financial Officer, Judy Hong, effective immediately (the "Separation").”
“Effective as of Mr. Stewart's transition on August 14, 2023, Judy Hong, the Company's Chief Financial Officer ("CFO") and Principal Financial Officer, was designated as the Company's Principal Accounting Officer.”
“I'll start by reviewing our fourth quarter and full-year fiscal 2025 results, including performance by key business unit. I'll then discuss progress on our balance sheet and cash flow, followed by an update on Canopy USA, and I'll end with a discussion on our priorities and outlook for fiscal 2026.”
“I'll start by walking through our Q3 fiscal 2025 results, including performance by key business units. I'll then discuss progress on our balance sheet and cash flow, followed by a discussion on our priorities and outlook for the balance of fiscal 2025 and into fiscal 2026.”
“I'll start by reviewing our second quarter fiscal 2025 results, including performance by key business units. I'll then discuss continued progress we've made on our balance sheet and cash flow, followed by a discussion on our priorities and outlook for the balance of fiscal 2025.”
“I'll start by reviewing our first quarter fiscal 2025 results. I'll then discuss continued progress we've made on our balance sheet and cash flow, followed by a discussion on our priorities and outlook for the balance of fiscal 2025.”
“I'll start by reviewing our fourth-quarter and full-year fiscal 2024 results, including the significant progress we've made across our P&L this year. I'll then discuss additional actions that we've taken to improve our balance sheet and cash flow, followed by our priorities and outlook for fiscal 2025.”
2023-08-14–present
Start not stated–present
Last confirmed August 7, 2026
Start not stated–2025-07-09
Drug Manufacturers - Specialty & Generic · Healthcare
Head of Investor Relations, CFO, Chief Accounting Officer
2023-08-14–present
Compensation components disclosed in company proxy statements. Amounts are nominal USD; total is the company-reported figure.
| Fiscal year | Company | Role | Salary | Total |
|---|---|---|---|---|
| 2024 | Canopy Growth Corp (CGC) | CFO | $410,960 | $2,303,063 |
| 2023 | Canopy Growth Corp (CGC) | CFO | $391,221 | $2,641,533 |
| 2022 | Canopy Growth Corp (CGC) | CFO | $283,744 | $834,708 |